Skip to main content

Table 3 Number of cycles and patients with treatment-related adverse events in >20% of patients (N = 24 patients)

From: Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

  Grade (number of cycles) Patients
  1 2 3 4 Number %
Alkaline phosphatase increased 6     5 21%
Dysphagia 2 2 1   5 21%
Dyspnea 5 3 2   5 21%
Hypoalbuminemia 3 1 1   5 21%
Dehydration 3 5 1   7 29%
Fever 8     7 29%
Hypokalemia 11 1 4 2 7 29%
Transaminases increased 11     7 29%
Hypertriglyceridemia 7 1 1   8 33%
Peripheral sensory neuropathy 8 3    8 33%
Vomiting 7 1 4   8 33%
Anorexia 7 4    9 38%
Urinary tract infection 1 6 2   9 38%
Diarrhea 8 6 1   10 42%
Hyperglycemia 18 6 2   10 42%
Hypomagnesemia 23 6    10 42%
Mucositis oral 10 10 2   11 46%
White blood cell decreased 14 14 29 3 12 50%
Nausea 17 4 3   13 54%
Pain 7     13 54%
Alopecia 8 12    14 58%
Fatigue 14 14 1   15 63%
Anemia 21 45 15   20 83%
Platelet count decreased 32 26 14 14 20 83%
Neutrophil count decreased 8 19 26 20 21 88%
  1. Toxicities by grade seen in >20% of patients deemed possibly, probably, or definitely related in all patients eligible for toxicity evaluation. Under grade, this is listed as: Total Number of Cycles. Under Patients, this is listed as the: Total Number of Patients for any grade. There were 24 patients who received at least 1 dose of treatment and were part of the toxicity evaluation. A patient may be counted only once for each grade of toxicity but may appear under more than one grade for each toxicity